Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Overweight · Obesity
Phase 3
Recruiting
336
2026-05
Industry sponsor intelligence
Innovent Biologics (Suzhou) Co. Ltd.Clinical Pipeline.
Lead-sponsor view of Innovent Biologics (Suzhou) Co. Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 20
- Recruiting
- 5
- Active
- 3
- Completed
- 12
- Results posted
- 0
- Avg enrollment
- 247
Pipeline overview
Programs by phase and activity.
Velocity
Innovent Biologics (Suzhou) Co. Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
23phase labels
Early Phase 10
Phase 17
Phase 27
Phase 39
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Mazdutide → | 20 | 7 | 7 | 9 | 0 | 8 |
| Dulaglutide → | 2 | 0 | 1 | 1 | 0 | 0 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Innovent Biologics (Suzhou) Co. Ltd. · Overweight · Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Phase 3
Active, not recruiting
479
2026-05
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Innovent Biologics (Suzhou) Co. Ltd. · Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Phase 3
Recruiting
180
2026-01
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Obesity
Phase 1 / Phase 2
Active, not recruiting
98
2025-12
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Innovent Biologics (Suzhou) Co. Ltd. · Metabolic Dysfunction-associated Steatohepatitis (MASH)
Phase 2
Recruiting
165
2025-11
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Obesity · Heart Failure With Preserved Ejection Fraction (HFPEF)
Phase 2
Recruiting
141
2025-07
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Innovent Biologics (Suzhou) Co. Ltd. · Sleep Apnea · Obstructive
Phase 3
Recruiting
260
2025-06
A Study of IBI362 9 mg in Chinese Adults With Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Obesity
Phase 3
Active, not recruiting
462
2024-08
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes · Obesity
Phase 3
Completed
349
2026-06
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
Innovent Biologics (Suzhou) Co. Ltd. · Overweight/ Obesity
Phase 2
Completed
328
2025-11
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Adolescents With Obesity
Phase 1
Completed
36
2025-09
A Study of IBI362 in Participants With Obesity or Overweight
Innovent Biologics (Suzhou) Co. Ltd. · Obesity Or Overweight
Phase 3
Completed
610
2024-11
A Study of IBI362 in Participants With Type 2 Diabetes
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes
Phase 3
Completed
731
2024-08
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes
Phase 3
Completed
319
2024-08
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
Innovent Biologics (Suzhou) Co. Ltd. · Renal Impairment
Phase 1
Completed
20
2024-02
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes
Phase 2
Completed
252
2023-12
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Innovent Biologics (Suzhou) Co. Ltd. · Overweight or Obesity
Phase 1 / Phase 2
Completed
60
2023-11
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
Innovent Biologics (Suzhou) Co. Ltd. · Overweight Subjects · Obese Subjects
Phase 1
Completed
48
2023-11
Showing 10 of 12 studies
Search sponsor records
All Innovent Biologics (Suzhou) Co. Ltd. studies.
This page groups studies where Innovent Biologics (Suzhou) Co. Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
20 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT06184568A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityJun 11, 2026NCT07469800Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityMay 27, 2026NCT06884293A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）May 12, 2026NCT07255209A Study of IBI362 in Chinese Adolescents With Obesity or OverweightJan 8, 2026NCT07000955Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityDec 15, 2025NCT06937749A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Nov 20, 2025NCT04904913A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsNov 17, 2025NCT06536023This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With ObesitySep 12, 2025NCT06862908A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityJul 11, 2025NCT06931028A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2Jun 29, 2025